【结 构 式】 |
【药物名称】CP-B, CMP-3 【化学名称】7-[2(S)-[3(R)-Hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrrolidin-1-yl]heptanoic acid 【CA登记号】346672-61-5 【 分 子 式 】C22H30F3NO4 【 分 子 量 】429.4839 |
【开发单位】Pfizer (Originator) 【药理作用】Bone Diseases, Treatment of, METABOLIC DRUGS, Treatment of Osteoporosis, Prostanoid EP4 Agonists |
合成路线1
Alkylation of (R)-5-(t-butyldimethylsilyloxymethyl)pyrrolidin-2-one (I) with ethyl 7-bromoheptanoate (II) affords the pyrrolidone-ester (III). After removal of the silyl protecting group of (III) with tetrabutylammonium fluoride, the resultant alcohol (IV) is oxidized to aldehyde (V) under modified Swern conditions, using DMSO/EDC
【1】 Cameron, K.O.; Crawford, D.T.; DaSilva-Jardine, P.; et al.; Discovery and bone anabolic activity of highly selective EP4 receptor prostaglandin E2 (PGE2) agonists. 224th ACS Natl Meet (Aug 18 2002, Boston) 2002, Abst MEDI 307. |
【2】 Thompson, D.D.; Lefker, B.A.; Cameron, K.O.; Ke, H.Z. (Pfizer Products Inc.); EP4 receptor selective agonists in the treatment of osteoporosis. EP 1110949; JP 2001181210; WO 0146140 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 60581 | (5R)-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyrrolidinone | C11H23NO2Si | 详情 | 详情 | |
(II) | 36428 | ethyl 7-bromoheptanoate | 29823-18-5 | C9H17BrO2 | 详情 | 详情 |
(III) | 60582 | ethyl 7-[(2R)-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-oxopyrrolidinyl]heptanoate | C20H39NO4Si | 详情 | 详情 | |
(IV) | 60583 | ethyl 7-[(2R)-2-(hydroxymethyl)-5-oxopyrrolidinyl]heptanoate | C14H25NO4 | 详情 | 详情 | |
(V) | 60584 | ethyl 7-[(2R)-2-formyl-5-oxopyrrolidinyl]heptanoate | C14H23NO4 | 详情 | 详情 |
合成路线2
[3-(Trifluoromethyl)phenyl]acetic acid (VI) is coupled to N,O-dimethylhydroxylamine to produce the N-methoxy amide (VII). Subsequent condensation of methoxyamide (VII) with dimethyl methylphosphonate (VIII) in the presence of BuLi leads to the oxo phosphonate (IX). Horner-Emmons condensation of phosphonate (IX) with aldehyde (V) furnishes enone (X). Diastereoselective reduction of (X) by means of catecholborane in the presence of (R)-2-methyl-CBS-oxazaborolidine in cold CH2Cl2 provides the allylic alcohol (XI) as the major isomer. Subsequent catalytic hydrogenation of (XI) gives the saturated alcohol (XII). Finally, basic hydrolysis of the ethyl ester group of (XII) produces the target carboxylic acid
【1】 Cameron, K.O.; Crawford, D.T.; DaSilva-Jardine, P.; et al.; Discovery and bone anabolic activity of highly selective EP4 receptor prostaglandin E2 (PGE2) agonists. 224th ACS Natl Meet (Aug 18 2002, Boston) 2002, Abst MEDI 307. |
【2】 Thompson, D.D.; Lefker, B.A.; Cameron, K.O.; Ke, H.Z. (Pfizer Products Inc.); EP4 receptor selective agonists in the treatment of osteoporosis. EP 1110949; JP 2001181210; WO 0146140 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(V) | 60584 | ethyl 7-[(2R)-2-formyl-5-oxopyrrolidinyl]heptanoate | C14H23NO4 | 详情 | 详情 | |
(VI) | 60585 | 2-[3-(trifluoromethyl)phenyl]acetic acid | C9H7F3O2 | 详情 | 详情 | |
(VII) | 60586 | N-methoxy-N-methyl-2-[3-(trifluoromethyl)phenyl]acetamide | C11H12F3NO2 | 详情 | 详情 | |
(VIII) | 13607 | dimethyl methylphosphonate | 756-79-6 | C3H9O3P | 详情 | 详情 |
(IX) | 60587 | dimethyl 2-oxo-3-[3-(trifluoromethyl)phenyl]propylphosphonate | C12H14F3O4P | 详情 | 详情 | |
(X) | 60588 | ethyl 7-((5R)-2-oxo-5-{(E)-3-oxo-4-[3-(trifluoromethyl)phenyl]-1-butenyl}pyrrolidinyl)heptanoate | C24H30F3NO4 | 详情 | 详情 | |
(XI) | 60589 | ethyl 7-((2R)-2-{(E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-butenyl}-5-oxopyrrolidinyl)heptanoate | C24H32F3NO4 | 详情 | 详情 | |
(XII) | 60590 | ethyl 7-((2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidinyl)heptanoate | C24H34F3NO4 | 详情 | 详情 |